Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-03T02:48:07.307Z Has data issue: false hasContentIssue false

Ten Years of Prospective Clostridium difficile-Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center, 1982–1991

Published online by Cambridge University Press:  02 January 2015

Mary M. Olson*
Affiliation:
Departments of Surgery, Laboratory Medicine, and Medicine, Veterans Affairs Medical Center, and the University of Minnesota Medical School, Minneapolis, Minnesota
Carol J. Shanholtzer
Affiliation:
Departments of Surgery, Laboratory Medicine, and Medicine, Veterans Affairs Medical Center, and the University of Minnesota Medical School, Minneapolis, Minnesota
James T. Lee Jr
Affiliation:
Departments of Surgery, Laboratory Medicine, and Medicine, Veterans Affairs Medical Center, and the University of Minnesota Medical School, Minneapolis, Minnesota
Dale N. Gerding
Affiliation:
Departments of Surgery, Laboratory Medicine, and Medicine, Veterans Affairs Medical Center, and the University of Minnesota Medical School, Minneapolis, Minnesota
*
Department of Surgery (112), VA Medical Center, 1 Veterans Dr., Minneapolis, MN 55417

Abstract

Objectives:

To understand the epidemiology, risks, and management of Clostridium difficile -associated disease (CDAD) and to establish and evaluate reliable methods of surveillance.

Design:

Case finding was done by daily ward and laboratory rounds. The criteria for CDAD diagnosis were: at least four unformed stools per day for 2 days and a positive culture or cytotoxin for C difficile, or positive endoscopy or autopsy for pseudomembranes.

Setting:

The surveillance covered all patients from 1982 through 1991 in the 820-bed Minneapolis Veterans Affairs Medical Center.

Participants:

The criteria were met by 908 patients. Medical service patients numbered 488; surgical patients, 420. Frequencies ranged from a high of 149 cases in 1982 to a low of 50 cases in 1989.

Results:

Stool specimens were obtained on 898 (99%) of the 908 CDAD patients. Stools were culture-positive in 864 (96%) of 898, cytotoxin-positive in 569 (63%) of 898. Endoscopy was performed on 196 (22%) of the 908 patients, and 80 (41%) of 196 patients had pseudomembranes. Ten (1%) of the 908 patients were diagnosed by endoscopy without a stool specimen, or at autopsy. No treatment was needed for 135 (15%) of the 908 CDAD patients, and 19 (2%) of the 908 died before treatment was started. Oral metronidazole was the treatment for 632 (70%) of 908 patients (1% intolerance, 2% failure, 7% relapse) and oral vancomycin was given to 122 (13%) of 908 patients (1% intolerance, 1% failure, 10% relapse). Twelve patients had pseudomembranous colitis at autopsy, and it was the primary cause of death in 5 (0.6%) of 908.

Conclusions:

CDAD usually responds to oral metronidazole or vancomycin but is nonetheless responsible for a high morbidity and occasional mortality in patients even when the diagnosis and treatment are pursued aggressively.

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Gerding, DN, Olson, MM, Peterson, LR, et al. Clostridium dificile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95100.CrossRefGoogle ScholarPubMed
2. Gerding, DN, Olson, MM, Johnson, S, Peterson, LR, Lee, JT. Clostridium difficile diarrhea and colonization after treatment with abdominal infection regimens containing clindamycin or metronidazole. Am J Surg 1990;159:212217.CrossRefGoogle ScholarPubMed
3. George, WL, Sutter, YL, Goldstein, EJC, et al. Aetiology of antimicrobial agent-associated colitis. Lancet 1979;1:802803.Google Scholar
4. Shanholtzer, CJ, Willard, KE, Holter, JJ, et al. Comparison of VIDAS Clostridium difficile toxin A immunoassay with C dificile culture and cytotoxin and latex tests. J Clin Microbial 1992;30:18371840.CrossRefGoogle Scholar
5. Shanholtzer, CJ, Peterson, LR. Laboratory quality assurance testing of microbiological media from commercial sources. Am J Clin Pathol 1987;88:210215.CrossRefGoogle ScholarPubMed
6. Shanholtzer, CJ, Peterson, LR, Olson, MM, Gerding, DN. Prospective study of Gram stain stool smears in diagnosis of Clostridium difficile . J Clin Microbial 1983;7:906908.CrossRefGoogle Scholar
7. Kelly, PJ, Peterson, LR. The role of the clinical microbiology laboratory in the management of Clostridium dificile-associated diarrhea. Infect Dis Clin North Am 1993;7:277293.Google Scholar
8. Clabots, CR Johnson, S, Olson, MM, Peterson, LR, Gerding, DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561567.Google Scholar
9. Teasley, DG, Gerding, DN, Olson, MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium dificile-associated diarrhoea and colitis. Lancet 1983;2:10431046.CrossRefGoogle ScholarPubMed
10. Morris, JB, Zollinger, RM, Stellato, TA. Role of surgery in antibiotic-induced pseudomembranous enterocolitis. Am J Surg 1990;160:535539.CrossRefGoogle ScholarPubMed
11. Johnson, S, Gerding, DN, Olson, MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990;88:137140.CrossRefGoogle ScholarPubMed
12. Johnson, S, Homann, SR, Bettin, KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann Intern Med 1992;117:297302.CrossRefGoogle ScholarPubMed